Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology

American Journal of Transplantation

Volumn 7, Issue 2, 2007, Pages 366-376

  Nankivell, B J ^a   Wavamunno, M D ^a   Borrows, R J ^a   Vitalone, M ^a   Fung, C L S ^a   Allen, R D M ^a   Chapman, J R ^a   O'Connell, P J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Azathioprine; Chronic allograft nephropathy; Cyclosporine nephrotoxicity; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GRAFT RECIPIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; MORPHOMETRICS; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; FIBROSIS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33846189299     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01633.x     Document Type: Article

References (42)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
2. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450-1454.
3. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.
4. Schnuelle P, van der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536-543.
5. Francois H, Durrbach A, Amor M et al. The long-term effect of switching from cyclosporin A tomycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 2003; 18: 1909-1916.
6. Ducloux D, Motte G, Billerey C et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: A 2-year follow-up. Transpl Int 2002; 15: 387-392.
7. Gonzalez Molina M, Seron D, Garcia del Moral R et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215-220.
8. Henne T, Latta K, Strehlau J, Pape L, Ehrich JH, Offner G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76: 1326-1330.
9. Badid C, Vincent M, McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
10. Dubus I, L'Azou B, Gordien M et al. Cytoskeletal reorganization by mycophenolic acid alters mesangial cell migration and contractility. Hypertension 2003; 42: 956-961.
11. Dubus I, Vendrely B, Christophe I et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002; 62: 857-867.
12. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
13. Heinz C, Hudde T, Heise K, Steuhl KP. Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts. Graefes Arch Clin Exp Ophthalmol 2002; 240: 408-414.
14. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
15. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003; 41: 465-469.
16. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460-466.
17. Bayazit AK, Bayazit Y, Noyan A, Gonlusen G, Anarat A. Comparison of mycophenolate mofetil and azathioprine in obstructive nephropathy. Pediatr Nephrol 2003; 18: 100-104.
18. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3: 342-351.
19. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945-955.
20. Ryuzo M, Soares V. Effect of mycophenolate mofetil on the progression of adriamycin nephropathy. Ren Fail 2001; 23: 611-619.
21. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 1550-1559.
22. Tapia E, Franco M, Sanchez-Lozada LG et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003; 63: 994-1002.
23. Van den Branden C, Ceyssens B, Pauwels M et al. Effect of mycophenolate mofetil on glomerulosclerosis and renal oxidative stress in rats. Nephron Exp Nephrol 2003; 95: e93-99.
24. Zhang C, Zhu Z, Wang G, Deng A. Effects of mycophenolate mofetil on renal interstitial fibrosis after Unilateral ureteral obstruction in rats. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 269-270, 282.
25. Yu CC, Yang CW, Wu MS et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med 2001; 138: 69-77.
26. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
27. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
28. Caramori ML, Basgen JM, Mauer M. Glomerular structure in the normal human kidney: Differences between living and cadaver donors. J Am Soc Nephrol 2003; 14: 1901-1903.
29. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994; 43: 1358-1364.
30. Deierhoi MH, Sollinger HW, Diethelm AG, Belzer FO, Kauffman RS. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 1993; 25: 693-694.
31. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 2055-2066.
32. Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502.
33. Jolicoeur EM, Qi S, Xu D, Dumont L, Daloze P, Chen H. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 2003; 75: 54-59.
34. Pan F, Ebbs A, Wynn C et al. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation 2003; 75: 1110-1114.
35. Fujihara CK, Malheiros DM, Zatz R, Noronha ID. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-1519.
36. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1. Transplantation 2004; 77: 683-686.
37. Kuypers DR, Vanrenterghem Y, Squifflet JP et al. Twelvemonth evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609-622.
38. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011-1017.
39. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461-468.
40. Hueso M, Bover J, Seron D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727-1731.
41. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
42. Haug C, Schmid-Kotsas A, Linder T et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002; 103: 76S-80S.